Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly shot could help diabetics with kidney trouble control blood sugar

NCT ID NCT06297603

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tests a once-weekly injection called retatrutide in 320 adults with type 2 diabetes and moderate to severe kidney disease who are not controlling their blood sugar well on insulin. Participants will receive either the drug or a placebo for about 14 months. The goal is to see if retatrutide safely improves blood sugar levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
retatrutide (a once-weekly injection)
What this could lead to
If it works, retatrutide could offer a new treatment option to help control blood sugar in people with type 2 diabetes and kidney problems.
What could go wrong
This is a phase 3 trial, but it is still experimental. The drug may not work better than placebo, and side effects are possible. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have Type 2 Diabetes (T2D) * Have HbA1c ≥7.0% (53 millimoles per mole (mmol/mol)) to ≤10.5% (91 mmol/mol) * Have moderate or severe renal impairment * Have been on the following stable diabetes treatment during 90 days prior to screening * basal insulin (≥20 International Units (IU)/day) with or without * metformin and/or SGLT2 inhibitor * Are of stable weight for at least 90 days prior to screening * Have a Body Mass Index (BMI) ≥23.0 kilograms per meter squared (kg/m2) Exclusion Criteria: * Have Type 1 Diabetes (T1D) * Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening * Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * Have a history of unstable or rapidly progressing renal disease * Have a prior or planned surgical treatment for obesity * Have New York Heart Association Functional Classification III or IV congestive heart failure * Have had acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening * Have a known clinically significant gastric emptying abnormality * Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years * Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2. * Have any lifetime history of a suicide attempt * Had chronic or acute pancreatitis * Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome diabetes mellitus endocrine system disorder glucose metabolism disease kidney disorder metabolic disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • AM Diabetes & Endocrinology Center

    Bartlett, Tennessee, 38133, United States

  • Albany Medical College, Division of Community Endocrinology

    Albany, New York, 12203, United States

  • Billings Clinic

    Billings, Montana, 59101, United States

  • CARE Institute

    Idaho Falls, Idaho, 83404, United States

  • CEDIC

    CABA, C1060ABN, Argentina

  • CEDOES

    Vitória, 29055450, Brazil

  • CIMeL

    Lanus, B1824KAJ, Argentina

  • CIPREC

    Buenos Aires, C1061AAS, Argentina

  • CIPREC

    Buenos Aires, C1119ACN, Argentina

  • Central States Research

    Tulsa, Oklahoma, 74136, United States

  • Centro Diabetológico Dr. Waitman

    Córdoba, 5000, Argentina

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

    Buenos Aires, C1425AGC, Argentina

  • Centro Médico Colón

    Córdoba, X5003DCP, Argentina

  • Centro Médico Viamonte

    Buenos Aires, C1120AAC, Argentina

  • Centro de Diabetes Curitiba

    Curitiba, 80810-040, Brazil

  • Centro de Endocrinologia Alcantara Gonzalez

    Bayamón, 00956, Puerto Rico

  • Centro de Investigaciones Clínicas Baigorria

    Granadero Baigorria, 2152, Argentina

  • Centro de Investigaciones Metabólicas (CINME)

    Buenos Aires, C1056ABI, Argentina

  • Centro de Investigaciones Médicas Mar del Plata

    Mar del Plata, 7600, Argentina

  • Centro de Pesquisas Clínicas Dr. Marco Mota

    Maceió, 57051-160, Brazil

  • Clalit Health Services - Atlit

    Atlit, 3032301, Israel

  • Clalit Health Services - Sakhnin Community Clinic

    Sakhnin, 3081000, Israel

  • Clinical Research Institute of Arizona (CRI) - Sun City West

    Sun City West, Arizona, 85375, United States

  • Cotton O'Neil Diabetes & Endocrinology

    Topeka, Kansas, 66606, United States

  • DIM Clínica Privada

    Ramos Mejía, B1704ETD, Argentina

  • Diabetes & Endocrine Treatment Specialists

    Sandy City, Utah, 84093, United States

  • Diseno y Planeacion en Investigacion Medica

    Guadalajara, 44130, Mexico

  • Edinburgh Royal Infirmary

    Edinburgh, EH16 4SA, United Kingdom

  • Edith Wolfson Medical Center

    Holon, 5810001, Israel

  • Enclifar Ensayos Clínicos Farmacológicos Sc

    Chihuahua City, 31110, Mexico

  • Encore Medical Research - Weston

    Weston, Florida, 33331, United States

  • EndoTrials Center for Clinical Research

    La Mesa, California, 91942, United States

  • Excel Clinical Research, LLC

    Las Vegas, Nevada, 89109, United States

  • FAICIC S. de R.L. de C.V.

    Veracruz, 91900, Mexico

  • George Eliot Hospital

    Nuneaton, CV10 7DJ, United Kingdom

  • Hadassah Medical Center

    Jerusalem, 9112001, Israel

  • Hope Clinical Research, Inc.

    Canoga Park, California, 91303, United States

  • IBPClin - Instituto Brasil de Pesquisa Clínica

    Rio de Janeiro, 20241-180, Brazil

  • INECO Neurociencias Oroño

    Rosario, 2000, Argentina

  • Institute of Diabetes, Technology and Research - Clalit Health

    Herzliya, 4630945, Israel

  • Instituto Médico Catamarca IMEC

    Rosario, 2000, Argentina

  • Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica

    Rosario, 2000, Argentina

  • Instituto de Ensino e Pesquisa Clinica do Ceara

    Fortaleza, 60125058, Brazil

  • Instituto de Investigaciones Clinicas Rosario

    Rosario, S2000CVD, Argentina

  • Instituto de Pesquisa Clinica

    São Paulo, 01223-001, Brazil

  • Investigaciones Medicas Imoba Srl

    Buenos Aires, C1056ABH, Argentina

  • Isis Clinical Research Center

    Guaynabo, 00968, Puerto Rico

  • Juno Research

    Houston, Texas, 77040, United States

  • Kidney & Hypertension Center - Apple Valley

    Apple Valley, California, 92307, United States

  • Lister Hospital

    Stevenage, SG1 4AB, United Kingdom

  • Mautalen Salud e Investigación

    Buenos Aires, C1128AAF, Argentina

  • Medical Care and Research SA de CV

    Mérida, 97070, Mexico

  • Mgcendo Llc

    San Juan, 00921, Puerto Rico

  • NYC Research INC

    Long Island City, New York, 11106, United States

  • Neighborhood Healthcare Institute of Health

    Escondido, California, 92025, United States

  • Nephrology Consultants

    Huntsville, Alabama, 35805, United States

  • Northeast Research Institute (NERI)

    Fleming Island, Florida, 32003, United States

  • Orita Clinical Research

    Decatur, Georgia, 30034, United States

  • Panthera Biopartners - Glasgow

    Glasgow, G51 4LB, United Kingdom

  • Panthera Biopartners - Manchester

    Rochdale, OL11 4AU, United Kingdom

  • Panthera Biopartners - Preston

    Preston, PR2 9QB, United Kingdom

  • PlanIt Research, PLLC

    Houston, Texas, 77079, United States

  • Praxis Pesquisa Medica

    Santo André, 09790790, Brazil

  • Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair

    Pittsburgh, Pennsylvania, 15243, United States

  • Prime Revival Research Institute, LLC

    Flower Mound, Texas, 75098, United States

  • Research Foundation of SUNY - University of Buffalo

    Williamsville, New York, 14221, United States

  • Salford Royal Hospital

    Salford, M6 8HD, United Kingdom

  • Sheba Medical Center

    Ramat Gan, 5262100, Israel

  • Soroka Medical Center

    Beersheba, 8410101, Israel

  • Southern Endocrinology Associates

    Mesquite, Texas, 75149, United States

  • Southmead Hospital

    Bristol, BS10 5NB, United Kingdom

  • Texas Valley Clinical Research

    Weslaco, Texas, 78596, United States

  • The Royal Cornwall Hospital

    Truro, TR1 3LJ, United Kingdom

  • UCLA South Bay Endocrinology

    Torrance, California, 90505, United States

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina, 27514, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.